<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9160">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05704088</url>
  </required_header>
  <id_info>
    <org_study_id>MD.21.12.574</org_study_id>
    <nct_id>NCT05704088</nct_id>
  </id_info>
  <brief_title>SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients</brief_title>
  <official_title>SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Diabetic and Non- Diabetic Lupus Nephritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this Randomized, controlled trial in 100 patients with LN with an estimated&#xD;
      glomerular filtration rate (eGFR) of 25-75 ml/min/1.73m2. Diagnosis of LN was performed by&#xD;
      renal biopsy, and all of the renal biopsies were carried out at urology and nephrology&#xD;
      center.&#xD;
&#xD;
      1. The main questions it aims to answer are:&#xD;
&#xD;
        -  Assess the role of sodium glucose co transporter 2 inhibitors (SGLT2i) in regression of&#xD;
           ongoing kidney and cardiac diseases among diabetic or non-diabetic patients with lupus&#xD;
           nephritis (LN) under different immunosuppressive therapies.&#xD;
&#xD;
        -  Investigate the impact of SGLT2i on bone and mineral metabolism in these patients.&#xD;
&#xD;
      Participants will be randomized into two groups :&#xD;
&#xD;
        -  Study group: will receive SGLT2i as add on drug or replace another drug according to the&#xD;
           patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without&#xD;
           food.&#xD;
&#xD;
        -  Control group: will be maintained on their medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study sitting: Nephrology and renal transplant unit at urology and nephrology center in&#xD;
      Mansoura University.&#xD;
&#xD;
      Study design and sample size:&#xD;
&#xD;
      Randomized, controlled trial that will include 100 patients with Lupus nephritis (LN) with an&#xD;
      estimated glomerular filtration rate of 25-75 ml/min/1.73m2. Diagnosis of LN was performed by&#xD;
      renal biopsy, and all of the renal biopsies were carried out at urology and nephrology&#xD;
      center.&#xD;
&#xD;
      The patients will be randomized into two groups Study group: will receive SGLT2i as add on&#xD;
      drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg&#xD;
      will be used once daily with or without food.&#xD;
&#xD;
      Control group: will be maintained on their medication.&#xD;
&#xD;
      Study Protocol:&#xD;
&#xD;
      Patients in the study group will treated with dapagliflozin initiated at a total daily dosage&#xD;
      of 10 mg once daily.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      The following data will be gathered and evaluated for all patients:&#xD;
&#xD;
      I-before intervention:&#xD;
&#xD;
      Patients of both groups will be subjected to full history taking including duration of LN and&#xD;
      drug history and routine clinical examination including blood pressure and BMI measurements.&#xD;
&#xD;
      Laboratory investigations:&#xD;
&#xD;
      Serum creatinine, Creatinine clearance. 24 hour urine protein, urine protein/creatinine&#xD;
      ratio. Urine analysis. HBA1c. hemoglobin (HGB). Uric acid and lipid profile. Lupus serology.&#xD;
      immunoreactive parathyroid hormone (iPTH). Vitamin D level. Fibroblast growth factor 23&#xD;
      level. bone turnover markers : bone specific alkaline phosphates propeptides of type 1&#xD;
      procollagen tartrate resistant acid phosphatase 5b sclerostin level&#xD;
&#xD;
      Radiological investigation:&#xD;
&#xD;
      Quantitative computed tomography: to detect bone and mineral density (BMD). Cardiovascular&#xD;
      assessment: Echocardiography and vascular calcification incidence (NCCT model) : for&#xD;
      detection of coronary calcification.&#xD;
&#xD;
      II-after intervention:&#xD;
&#xD;
      All patients will be evaluated monthly regarding:&#xD;
&#xD;
      Regular measurement of blood pressure each visit.&#xD;
&#xD;
      Laboratory investigations:&#xD;
&#xD;
      Serum creatinine, creatinine clearance. 24 hour proteinuria, protein/creatinine ratio.&#xD;
      Fasting, random and postprandial glucose levels. calcineurin inhibitors (CNI) trough level if&#xD;
      used. Urine analysis. HGB level. Uric acid, lipid profile. Lupus serology.&#xD;
&#xD;
      All patients will be evaluated every 3 month regarding:&#xD;
&#xD;
        1. iPTH&#xD;
&#xD;
        2. Vitamin D level&#xD;
&#xD;
      All patients will be evaluated at 12 month regarding:&#xD;
&#xD;
        1. Fibroblast growth factor 23 level&#xD;
&#xD;
        2. High resolution quantitative computed tomography.&#xD;
&#xD;
        3. Bone turnover markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 8, 2022</start_date>
  <completion_date type="Anticipated">December 8, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 8, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled trial that will include 100 patients with LN with an estimated glomerular filtration rate (eGFR) of 25-75 ml/min/1.73m2. Diagnosis of LN was performed by renal biopsy, and all of the renal biopsies were carried out at urology and nephrology center.&#xD;
The patients will be randomized into two groups Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food.&#xD;
Control group: will be maintained on their medication.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effect of dapagliflozin on renal function</measure>
    <time_frame>1 year</time_frame>
    <description>Effect of dapagliflozin on eGFR (ml/ min).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>effect of dapagliflozin on kidney function</measure>
    <time_frame>1 year</time_frame>
    <description>Effect of dapagliflozin on s.creatinine (mg/dl).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>effect of dapagliflozin on BMD</measure>
    <time_frame>1 year</time_frame>
    <description>Effect of dapagliflozin on osteoporosis using Qct</description>
  </primary_outcome>
  <primary_outcome>
    <measure>effect of dapagliflozin on minerals</measure>
    <time_frame>1 year</time_frame>
    <description>Effect of dapagliflozin on serum calcium and phosphorus (mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>effect of dapagliflozin on Bone</measure>
    <time_frame>1 year</time_frame>
    <description>Effect of dapagliflozin on bone turnover markers (ng/dl)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>effect of dapagliflozin on blood pressure</measure>
    <time_frame>1 year</time_frame>
    <description>measuring systolic and diastolic blood pressure mmgh before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of dapagliflozin on body weight</measure>
    <time_frame>1 year</time_frame>
    <description>assessing body weight in kg before and after intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>SGLT2 INHIBITORS</condition>
  <condition>Lupus Nephritis</condition>
  <condition>BMD</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food for one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group: will receive placebo as add on drug once daily with or without food for one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin tablet</intervention_name>
    <description>randomized control trial, study group will receive dapagliflozin tablets</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>randomized control trial, control group will receive placebo tablets</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of patient is more than 18.&#xD;
&#xD;
          -  Patients who are willing to sign informed consent.&#xD;
&#xD;
          -  Patients with SLE diagnosed according to EULAR/ACR classification criteria.&#xD;
&#xD;
          -  Patients with LN according to renal biopsy.&#xD;
&#xD;
          -  Patients with eGFR &gt; 30 ml/min/1.73m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With eGFR &lt;30 ml/min per 1.73 m2.&#xD;
&#xD;
          -  Who is currently pregnancy or lactation.&#xD;
&#xD;
          -  With medical history of chronic disease (chronic liver disease, cancer, severe&#xD;
             respiratory distress, gastrointestinal tract lesions).&#xD;
&#xD;
          -  Refuse to participate in the study or lost follow up.&#xD;
&#xD;
          -  With evidence of urinary obstruction of difficulty in voiding at screening.&#xD;
&#xD;
          -  Who are receiving high dose diuretics or combined angiotensin-converting enzyme&#xD;
             inhibitor (ACEI) and Angiotensin II receptor blockers (ARBS).&#xD;
&#xD;
          -  Who have frequent hypotensive episode or systolic blood pressure &lt;100 mmHg. Active&#xD;
             malignancy.&#xD;
&#xD;
          -  Active infection including HIV.&#xD;
&#xD;
          -  Any medications that may affect or interact with bone metabolism such as calcitonin, ,&#xD;
             denosumab, estrogen and fluoride during the last 6 months.&#xD;
&#xD;
          -  Current or previous organ transplantation, or expected to get a kidney transplant&#xD;
             within 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Urology and Nephrology Center</name>
      <address>
        <city>Mansoura</city>
        <zip>35511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>January 19, 2023</last_update_submitted>
  <last_update_submitted_qc>January 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mohamed Hosny</investigator_full_name>
    <investigator_title>nephrology specialist at urology and nephrology center (principle investigator)</investigator_title>
  </responsible_party>
  <keyword>SGLT2 INHIBITORS</keyword>
  <keyword>BMD</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all individual participant data (IPD) that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

